HLX 94
Alternative Names: HLX-94Latest Information Update: 16 Feb 2024
At a glance
- Originator Shanghai Henlius Biotech
- Class Antiparkinsonians; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Parkinson's disease
Most Recent Events
- 15 Dec 2023 Preclinical trials in Amyotrophic lateral sclerosis in China (unspecified route) prior to December 2023 (Shanghai Henlius Biotech pipeline, December 2023)
- 15 Dec 2023 Preclinical trials in Parkinson's disease in China (unspecified route) prior to December 2023 (Shanghai Henlius Biotech pipeline, December 2023)